Alefacept for psoriasis and psoriatic arthritis.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 16239390.
- Also identified by PMC identifier 1766916.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Alefacept is a bioengineered fusion protein of soluble lymphocyte function antigen (LFA-3) with Fc fragments of IgG1. It is marketed in many countries for the treatment of moderate to severe psoriasis. This paper reviews the data supporting the use of alefacept in psoriasis and psoriatic arthritis.
Medical subject headings
- Immunosuppressive Agents
- Psoriasis
- Recombinant Fusion Proteins